Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aprea Therapeutics, Inc. (Nasdaq: APRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Aprea files reports with the U.S. Securities and Exchange Commission as a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol APRE.
Among the key documents available through EDGAR are Aprea’s Form 8-K current reports, which the company uses to furnish earnings press releases, clinical program updates, financing announcements, and changes to its corporate presentation slide decks. For example, recent 8-K filings reference quarterly financial results, clinical updates from the ACESOT-1051 WEE1 inhibitor trial and the ABOYA-119 ATR inhibitor trial, and the establishment of a recommended Phase 2 dose for ATRN-119. Other 8-Ks describe private placement financing and the extension of projected cash runway.
Investors can also use the filings feed to monitor how Aprea discusses its lead programs, APR-1051 and ATRN-119, in official documents, including descriptions of trial objectives, biomarker-defined patient populations, and risk factor language incorporated by reference in periodic reports. While this page focuses on real-time access to filings such as 8-Ks, users can also locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or prospectus supplements that relate to equity offerings mentioned in company news.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical milestones, financial condition, and strategic shifts like pausing monotherapy enrollment to consider combination therapies. The platform also surfaces new filings as they are posted to EDGAR, allowing close tracking of Aprea’s regulatory and disclosure history over time.
Aprea Therapeutics, Inc. filed a Form 8-K to report that it updated its corporate presentation slide deck on September 8, 2025. The updated investor presentation, dated September 2025, is included as Exhibit 99.1 and incorporated by reference. This is a routine corporate communication intended to provide updated information about the company to investors and other stakeholders.
Sio Capital Management, LLC reports beneficial ownership of 279,369 shares of Aprea Therapeutics common stock, representing 5.05% of the class as of June 30, 2025. The position is held for affiliated funds for which Sio is the registered investment adviser; Sio reports 0 sole voting or dispositive power and 279,369 shared voting and dispositive power.
The 5.05% figure is calculated using 5,525,172 shares outstanding as of April 22, 2025. The filing notes that the general partner and Michael Castor may be deemed to have influence over the accounts that own the shares, while expressly disclaiming beneficial ownership; the filer certifies the shares are held in the ordinary course of business and not to change or influence control.
Aprea Therapeutics reported cash and cash equivalents of $16.5 million and total assets of $17.3 million, with an accumulated deficit of $328.2 million. The company recorded a net loss of $7.17 million for the six months and used $6.8 million of cash in operating activities over the same period. Grant revenue declined to $0.28 million year-to-date, largely from reduced NIH funding. Research and development spending was $4.40 million for six months, driven by ATRN-119 and APR-1051 programs, and the company expects safety/efficacy data in the second half of the year with RP2D decisions expected in the first half of 2026. Management states existing cash is not sufficient to fund operations for at least twelve months and has concluded substantial doubt exists about its ability to continue as a going concern, and is seeking additional funding.
Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.